http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 08:01:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html <p>Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on developing emavusertib, announced the pricing of a public offering expected to raise approximately $5.6 million in gross proceeds before fees and expenses.</p> <p>The offering includes 3,733,334 shares of common stock, or pre-funded warrants in lieu thereof, paired with warrants to purchase up to 3,733,334 additional shares. The combined public offering price is $1.50 per share and accompanying common warrant, or $1.49 per pre-funded warrant and accompanying common warrant.</p> <p>The common warrants carry an exercise price of $1.75 per share, are exercisable immediately, and expire five years from the issuance date. The pre-funded warrants http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html Thu, 13 Aug 2026 08:01:17 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html <p>Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on developing emavusertib, announced the pricing of a public offering expected to raise approximately $5.6 million in gross proceeds before fees and expenses.</p> <p>The offering includes 3,733,334 shares of common stock, or pre-funded warrants in lieu thereof, paired with warrants to purchase up to 3,733,334 additional shares. The combined public offering price is $1.50 per share and accompanying common warrant, or $1.49 per pre-funded warrant and accompanying common warrant.</p> <p>The common warrants carry an exercise price of $1.75 per share, are exercisable immediately, and expire five years from the issuance date. The pre-funded warrants http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html Thu, 13 Aug 2026 08:01:17 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html <p>Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on developing emavusertib, announced the pricing of a public offering expected to raise approximately $5.6 million in gross proceeds before fees and expenses.</p> <p>The offering includes 3,733,334 shares of common stock, or pre-funded warrants in lieu thereof, paired with warrants to purchase up to 3,733,334 additional shares. The combined public offering price is $1.50 per share and accompanying common warrant, or $1.49 per pre-funded warrant and accompanying common warrant.</p> <p>The common warrants carry an exercise price of $1.75 per share, are exercisable immediately, and expire five years from the issuance date. The pre-funded warrants http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html Thu, 13 Aug 2026 08:01:17 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html <p>Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on developing emavusertib, announced the pricing of a public offering expected to raise approximately $5.6 million in gross proceeds before fees and expenses.</p> <p>The offering includes 3,733,334 shares of common stock, or pre-funded warrants in lieu thereof, paired with warrants to purchase up to 3,733,334 additional shares. The combined public offering price is $1.50 per share and accompanying common warrant, or $1.49 per pre-funded warrant and accompanying common warrant.</p> <p>The common warrants carry an exercise price of $1.75 per share, are exercisable immediately, and expire five years from the issuance date. The pre-funded warrants http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html Thu, 13 Aug 2026 08:01:17 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html <p>Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on developing emavusertib, announced the pricing of a public offering expected to raise approximately $5.6 million in gross proceeds before fees and expenses.</p> <p>The offering includes 3,733,334 shares of common stock, or pre-funded warrants in lieu thereof, paired with warrants to purchase up to 3,733,334 additional shares. The combined public offering price is $1.50 per share and accompanying common warrant, or $1.49 per pre-funded warrant and accompanying common warrant.</p> <p>The common warrants carry an exercise price of $1.75 per share, are exercisable immediately, and expire five years from the issuance date. The pre-funded warrants http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html Thu, 13 Aug 2026 08:01:17 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html <p>Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on developing emavusertib, announced the pricing of a public offering expected to raise approximately $5.6 million in gross proceeds before fees and expenses.</p> <p>The offering includes 3,733,334 shares of common stock, or pre-funded warrants in lieu thereof, paired with warrants to purchase up to 3,733,334 additional shares. The combined public offering price is $1.50 per share and accompanying common warrant, or $1.49 per pre-funded warrant and accompanying common warrant.</p> <p>The common warrants carry an exercise price of $1.75 per share, are exercisable immediately, and expire five years from the issuance date. The pre-funded warrants http://www.streetinsider.com/Equity+Offerings/Curis+prices+%245.6M+public+offering+at+%241.50+per+share/26916834.html Thu, 13 Aug 2026 08:01:17 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/Press+Releases/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of <money>$1.50</money> http://www.streetinsider.com/PRNewswire/Curis%2C+Inc.+Announces+Pricing+of+%245.6+Million+Public+Offering/26916769.html Thu, 13 Aug 2026 08:00:00 -0400 A.26693277 A.50202163 CRIS O.00176055 O.21906544 O.38677196 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++CURIS+INC++++++++++++++++++++++++++++/26915733.html si-local-file:///var/storage/secattach/20260813/26915733.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++CURIS+INC++++++++++++++++++++++++++++/26915733.html Thu, 13 Aug 2026 06:06:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++CURIS+INC++++++++++++++++++++++++++++/26915733.html si-local-file:///var/storage/secattach/20260813/26915733.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++CURIS+INC++++++++++++++++++++++++++++/26915733.html Thu, 13 Aug 2026 06:06:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++CURIS+INC++++++++++++++++++++++++++++/26899337.html si-local-file:///var/storage/secattach/20260810/26899337.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++CURIS+INC++++++++++++++++++++++++++++/26899337.html Mon, 10 Aug 2026 17:30:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++CURIS+INC++++++++++++++++++++++++++++/26899337.html si-local-file:///var/storage/secattach/20260810/26899337.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++CURIS+INC++++++++++++++++++++++++++++/26899337.html Mon, 10 Aug 2026 17:30:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Jul+24/26843350.html si-local-file:///var/storage/secattach/20260730/26843350.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Jul+24/26843350.html Thu, 30 Jul 2026 16:02:00 -0400 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Jul+24/26843350.html si-local-file:///var/storage/secattach/20260730/26843350.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Jul+24/26843350.html Thu, 30 Jul 2026 16:02:00 -0400 CRIS O.00176055 http://www.streetinsider.com/Corporate+News/Curis+doses+first+five+patients+in+CLL+study%2C+eyes+December+data/26839276.html <p>Curis, Inc. (NASDAQ: CRIS) announced it has dosed the first five patients in its TakeAim CLL study, a phase 2 trial evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia (CLL).</p><p>The Lexington, Mass.-based biotechnology company said the milestone meets a previously stated enrollment goal. Curis reaffirmed its expectation to report initial data from 5 to 10 patients in December 2026.</p><p>The TakeAim CLL study is an open-label phase 2 trial in which participants must be in a partial response or partial response with lymphocytosis, with measurable residual disease as determined by the clonoSEQ assay, and must have been http://www.streetinsider.com/Corporate+News/Curis+doses+first+five+patients+in+CLL+study%2C+eyes+December+data/26839276.html Thu, 30 Jul 2026 08:02:39 -0400 CRIS